Pharma & Life Sciences Business Valuation Calculator – India

India hosts the world's largest generic pharmaceutical manufacturing center (supplying ~20% of global generics by volume), where cost-competitive API production, massive ANDA filing capability, and increasingly sophisticated CDMO services create unique global supply chain positioning. Indian pharma M&A reflects this scale: global pharma acquires manufacturing capacity and cost advantages, PE drives consolidation across generics, API, and contract services, and domestic players pursue scale for competitive positioning.

What distinguishes Indian pharma valuations is the US FDA compliance status that determines export market access and dramatically affects company value. FDA-approved sites with clean inspection history command substantial premiums; Warning Letters or Import Alerts can discount valuations by 30-50% or more. ANDA filing portfolios, first-to-file (FTF) opportunities, and 180-day exclusivity positions directly affect valuations. API backward integration provides supply chain security increasingly valued post-COVID supply disruptions.

Valuation frameworks reflect manufacturing capability and regulatory positioning. Generic manufacturers trade on revenue or EBITDA multiples with ANDA portfolio breadth, FDA site compliance, and first-to-file positions affecting premiums. API manufacturers command premiums for backward integration capability and supply chain positioning. CDMO/CRO operations trade on capacity utilization, customer concentration, and quality track record. Domestic-focused companies trade on market share and pricing dynamics.

The buyer ecosystem reflects manufacturing opportunity: global pharma (Pfizer, Teva, Mylan/Viatris, Sandoz) acquires Indian manufacturing for cost advantages and capacity, PE drives consolidation across the value chain, Japanese pharma pursues Indian partnerships for generic capability, and domestic players pursue scale through M&A. Supply chain security considerations have increased strategic interest in API capability.

CDSCO regulates domestic market; US FDA, EMA, and other export market approvals determine international access. cGMP manufacturing compliance history is critical diligence area. WHO prequalification adds value for emerging market access. PLI (Production-Linked Incentive) scheme for APIs and formulations affects manufacturing investment decisions. Understanding promoter dynamics and related party transactions is essential.